The article discusses the use of factor V and thrombin inhibitors in patients with hemophilia and underwent aortic bioprosthetic valve replacement. Topics covered include the bioengineering of the leaflets with bovine pericardial tissue. Also mentioned are the benefits of patients from fibrin sealants.